3
H index
1
i10 index
30
Citations
Grace Hampson : Citation Profile
Office of Health Economics | RESEARCH PRODUCTION: 6 Articles 19 Papers RESEARCH ACTIVITY:
MORE DETAILS IN: ABOUT THIS REPORT:
|
6 years (2015 - 2021). Relations with other researchers
Works with:
Authors registered in RePEc who have co-authored more than one work in the last five years with Grace Hampson. | Is cited by:
| Cites to:
|
Main data
Where Grace Hampson has published?
| Journals with more than one article published | # docs |
|---|---|
| Applied Health Economics and Health Policy | 3 |
| Working Papers Series with more than one paper published | # docs |
|---|---|
| Research Papers / Office of Health Economics | 8 |
| Consulting Reports / Office of Health Economics | 7 |
| Briefings / Office of Health Economics | 4 |
Recent works citing Grace Hampson (2022 and 2021)
| Year | Title of citing document |
|---|---|
| 2021 | Variation in market access decisions for cell and gene therapies across the United States, Canada, and Europe. (2021). Chambers, James D ; Persson, Ulf ; Malone, Daniel C ; Sullivan, Sean D ; Fricke, Frank-Ulrich ; Drummond, Michael ; Dabbous, Omar ; Toumi, Mondher ; Neumann, Peter J ; Hanna, Eve ; Tunis, Sean. In: Health Policy. RePEc:eee:hepoli:v:125:y:2021:i:12:p:1550-1556. Full description at Econpapers || Download paper |
| 2021 | The Role of Patient Experience in the Value Assessment of Complex Technologies – Do HTA Bodies Need to Reconsider How Value is Assessed?. (2021). Upadhyaya, Sheela ; Kalo, Zoltan ; Bertelsen, Neil ; Brixner, Diana ; Mountian, Irina ; Szegvari, Boglarka ; Freitag, Andreas ; Sarri, Grammati. In: Health Policy. RePEc:eee:hepoli:v:125:y:2021:i:5:p:593-601. Full description at Econpapers || Download paper |
| 2022 | Promoting innovation while controlling cost: The UKs approach to health technology assessment. (2022). Mossialos, Elias ; Carter, Paul ; McGuire, Alistair ; Taylor, David ; Drummond, Michael ; Anderson, Michael. In: Health Policy. RePEc:eee:hepoli:v:126:y:2022:i:3:p:224-233. Full description at Econpapers || Download paper |
| 2021 | Which Criteria are Considered and How are They Evaluated in Health Technology Assessments? A Review of Methodological Guidelines Used in Western and Asian Countries. (2021). Francois, Clement ; Wang, Yitong ; Qiu, Tingting ; Toumi, Mondher ; Zhou, Junwen. In: Applied Health Economics and Health Policy. RePEc:spr:aphecp:v:19:y:2021:i:3:d:10.1007_s40258-020-00634-0. Full description at Econpapers || Download paper |
| 2022 | Value-based pricing for advanced therapy medicinal products: emerging affordability solutions. (2022). Gonalves, Elisabete. In: The European Journal of Health Economics. RePEc:spr:eujhec:v:23:y:2022:i:2:d:10.1007_s10198-021-01276-2. Full description at Econpapers || Download paper |
| 2021 | Common Problems, Common Data Model Solutions: Evidence Generation for Health Technology Assessment. (2021). Bouvy, Jacoline C ; Rijnbeek, Peter ; Hughes, Nigel ; Ostby, Jens Torup ; Jonsson, Pall ; Dawoud, Dalia ; Burn, Edward ; Kent, Seamus. In: PharmacoEconomics. RePEc:spr:pharme:v:39:y:2021:i:3:d:10.1007_s40273-020-00981-9. Full description at Econpapers || Download paper |
| 2021 | Methodological Challenges in the Economic Evaluation of a Gene Therapy for RPE65-Mediated Inherited Retinal Disease: The Value of Vision. (2021). Kanters, Tim A ; Schouten, Jan L ; Vegter, Stefan ; Versteegh, Matthijs M ; Huygens, Simone A. In: PharmacoEconomics. RePEc:spr:pharme:v:39:y:2021:i:4:d:10.1007_s40273-021-01003-y. Full description at Econpapers || Download paper |
| 2021 | Guidance for the Harmonisation and Improvement of Economic Evaluations of Personalised Medicine. (2021). Versteegh, Matthijs ; Huygens, Simone ; Vellekoop, Heleen ; Molken, Maureen Rutten-Van ; Wordsworth, Sarah ; Tsiachristas, Apostolos ; Koleva-Kolarova, Rositsa ; Nagy, Balazs ; Zelei, Tamas ; Szilberhorn, Laszlo. In: PharmacoEconomics. RePEc:spr:pharme:v:39:y:2021:i:7:d:10.1007_s40273-021-01010-z. Full description at Econpapers || Download paper |
| 2021 | Economic Evidence on Potentially Curative Gene Therapy Products: A Systematic Literature Review. (2021). Borle, Kennedy ; Ho, Joseph Khoa ; Lynd, Larry D ; Ross, Colin ; Kopac, Nicola ; Kitchin, Vanessa ; Dhillon, Manrubby ; Dragojlovic, Nick. In: PharmacoEconomics. RePEc:spr:pharme:v:39:y:2021:i:9:d:10.1007_s40273-021-01051-4. Full description at Econpapers || Download paper |
| 2021 | Real-World Evidence: Bridging Gaps in Evidence to Guide Payer Decisions. (2021). Ferguson, Gary T ; Roberts, Melissa H. In: PharmacoEconomics - Open. RePEc:spr:pharmo:v:5:y:2021:i:1:d:10.1007_s41669-020-00221-y. Full description at Econpapers || Download paper |
Works by Grace Hampson:
| Year | Title | Type | Cited |
|---|---|---|---|
| 2016 | New Age Decision Making in HTA: Is It Applicable in Asia? In: Briefings. [Full Text][Citation analysis] | paper | 0 |
| 2017 | Assessing Value, Budget Impact and Affordability to Inform Discussions on Access and Reimbursement: Principles and Practice, with Special Reference to High Cost Technologies In: Briefings. [Full Text][Citation analysis] | paper | 1 |
| 2017 | How can HTA meet the needs of health system and government decision makers? In: Briefings. [Full Text][Citation analysis] | paper | 0 |
| 2017 | Transferability of HTA In: Briefings. [Full Text][Citation analysis] | paper | 0 |
| 2016 | Four Case Studies to Explore the Added Value of Oxford AHSN In: Consulting Reports. [Full Text][Citation analysis] | paper | 0 |
| 2017 | Exploring the Assessment and Appraisal of Regenerative Medicines and Cell Therapy Products: Is the NICE Approach Fit for Purpose? In: Consulting Reports. [Full Text][Citation analysis] | paper | 1 |
| 2017 | Public Health and Economic Implications of the United Kingdom Exiting the EU and the Single Market In: Consulting Reports. [Full Text][Citation analysis] | paper | 1 |
| 2019 | Public Preferences for Health Gains and Cures: A Discrete Choice Experiment In: Consulting Reports. [Full Text][Citation analysis] | paper | 1 |
| 2020 | Opportunities to Increase Efficiency in Healthcare In: Consulting Reports. [Full Text][Citation analysis] | paper | 0 |
| 2021 | Exploring the Financial Sustainability of Gene Therapies In: Consulting Reports. [Full Text][Citation analysis] | paper | 0 |
| 2021 | Key Considerations for Early Access Schemes for Single-Administration (One-Time) Therapies In: Consulting Reports. [Full Text][Citation analysis] | paper | 0 |
| 2015 | Dementia: The R&D Landscape In: Research Papers. [Full Text][Citation analysis] | paper | 0 |
| 2016 | A Review of NICE Methods Across Health Technology Assessment Programmes: Differences, Justifications and Implications In: Research Papers. [Full Text][Citation analysis] | paper | 3 |
| 2016 | Applying a Multi-criteria Decision Analysis (MCDA) Approach to Elicit Stakeholders Preferences in Italy. The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL) In: Research Papers. [Full Text][Citation analysis] | paper | 0 |
| 2018 | Applying a Multicriteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy: The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL).(2018) In: PharmacoEconomics - Open. [Full Text][Citation analysis] This paper has another version. Agregated cites: 0 | article | |
| 2017 | Gene Therapy: Understanding the Science, Assessing the Evidence, and Paying for Value In: Research Papers. [Full Text][Citation analysis] | paper | 2 |
| 2017 | Macro Evaluation of the NIHR Oxford Biomedical Research Centre In: Research Papers. [Full Text][Citation analysis] | paper | 0 |
| 2018 | Real World Evidence for Coverage Decisions: Opportunities and Challenges In: Research Papers. [Full Text][Citation analysis] | paper | 6 |
| 2018 | Understanding the Context, Selecting the Standards: A Framework to Guide the Optimal Development and Use of Real-World Evidence for Coverage and Formulary Decisions In: Research Papers. [Full Text][Citation analysis] | paper | 0 |
| 2019 | HTA and Payment Mechanisms for New Drugs to Tackle AMR In: Research Papers. [Full Text][Citation analysis] | paper | 0 |
| 2017 | What Determines the Health Care Expenditure of High Income Countries? A Dynamic Estimation In: Applied Economics and Finance. [Full Text][Citation analysis] | article | 0 |
| 2017 | A Review of NICE Methods and Processes Across Health Technology Assessment Programmes: Why the Differences and What is the Impact? In: Applied Health Economics and Health Policy. [Full Text][Citation analysis] | article | 3 |
| 2020 | A Multinational European Study of Patient Preferences for Novel Diagnostics to Manage Antimicrobial Resistance In: Applied Health Economics and Health Policy. [Full Text][Citation analysis] | article | 1 |
| 2020 | Authors’ Reply to Hays: “A Multinational European Study of Patient Preferences for Novel Diagnostics to Manage Antimicrobial Resistance” In: Applied Health Economics and Health Policy. [Full Text][Citation analysis] | article | 0 |
| 2019 | Advanced therapy medicinal products and health technology assessment principles and practices for value-based and sustainable healthcare In: The European Journal of Health Economics. [Full Text][Citation analysis] | article | 11 |
CitEc is a RePEc service, providing citation data for Economics since 2001. Sponsored by INOMICS. Last updated August, 1st 2022. Contact: CitEc Team